Strides Shasun Receives EIR Report From USFDA

Published On 2016-06-08 08:56 GMT   |   Update On 2016-06-08 08:56 GMT

New Delhi : Drug firm Strides Shasun has received Establishment Inspection Report (EIR) from the US health regulator on closure of inspection of its oral dosage Facility at Bengaluru.


"The company's Oral Dosage Forms manufacturing site (KRS Gardens) in Bengaluru which was inspected by the USFDA in February 2016 has received the EIR, thereby confirming the closure of the inspection. The facility continues to be USFDA approved," Strides said in a BSE filing.


USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA contracted inspection when the agency determines the inspection to be closed.


Strides's KRS Gardens facility manufactures oral dosage forms including tablets, capsules (both hard and soft gelatine). The manufacturing plant supports important current and future submissions for the US market.


Shares of Strides Shasun were trading at Rs 1,129 apiece, up 0.96 per cent, from their previous close on the BSE.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News